Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.30 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2141501 | 0.77 | ADORA2B (0.38) | — | |
| SCHEMBL2363242 | 0.75 | HTT (0.48) | ALDH1A1HTTKDM4EHPGDHSD17B10 | |
| SCHEMBL3857960 | 0.70 | TPMT (0.39) | ALDH1A1HTTKDM4EHPGDHSD17B10 | |
| SCHEMBL20476086 | 0.70 | ALDH1A1 (0.39) | ALDH1A1HTTKDM4EHPGDHSD17B10 | |
| SCHEMBL2720873 | 0.70 | MAPK1 (0.38) | ALDH1A1HTTKDM4EPOLB | |
| SCHEMBL15258671 | 0.70 | HDAC3 (0.47) | — | |
| SCHEMBL2362049 | 0.69 | TACR3 (0.44) | ALDH1A1HTTSCN9AKDM4EHPGD | |
| SCHEMBL3560390 | 0.68 | SSTR4 (0.56) | ALDH1A1HTTKDM4EHPGDHSD17B10 | |
| SCHEMBL2712662 | 0.68 | SSTR4 (0.53) | ALDH1A1HTTSCN9AKDM4EHPGD | |
| SCHEMBL19029371 | 0.67 | HDAC6 (0.40) | ALDH1A1KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249094-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249094-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | HCAR2 3698/4885SLC1A3 3537/4885SLC1A2 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.